✦ LIBER ✦

P01-317 - Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric patients: Results from a 52-week open-label study

✍ Scribed by W. Landsberg; J.-Y. Loze; G. Lau; G. Manos; R. McQuade; L. Kamen; R. Marcus; R. Mankoski

Book ID: 119571107
Publisher: Elsevier Science
Year: 2011
Tongue: French
Weight: 31 KB
Volume: 26
Category: Article
ISSN: 0924-9338
DOI: 10.1016/s0924-9338(11)72028-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A 52-week open-label study of the safety

A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia

✍ Gopal, S.; Vijapurkar, U.; Lim, P.; Morozova, M.; Eerdekens, M.; Hough, D. 📂 Article 📅 2010 🏛 SAGE Publications 🌐 English ⚖ 288 KB

P.2.f.021 The safety and tolerability of

P.2.f.021 The safety and tolerability of vortioxetine in treating adults with major depressive disorder after 52 weeks of open-label treatment

✍ Baldwin, D.S.; Mahableshwarkar, A.R.; Chrones, L.; Palo, W.; Matz, J. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Open-label flexible-dose pilot study to

Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease

✍ Joseph H. Friedman; Robert M. Berman; Christopher G. Goetz; Stewart A. Factor; W 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 2 views

## Abstract Psychosis affects at least 5% to 8% of medication‐treated patients with idiopathic Parkinson's disease (PD). Treatment options include reducing medications used for the treatment of PD‐related motor symptoms or introducing an atypical antipsychotic drug. Only clozapine has been demonstr

Long-Term Safety and Efficacy of Donepez

Long-Term Safety and Efficacy of Donepezil in Patients with Dementia with Lewy Bodies: Results from a 52-Week, Open-Label, Multicenter Extension Study

✍ Ikeda, Manabu; Mori, Etsuro; Kosaka, Kenji; Iseki, Eizo; Hashimoto, Mamoru; Mats 📂 Article 📅 2013 🏛 S. Karger AG 🌐 English ⚖ 856 KB

P.4.006 Long-term efficacy and safety be

P.4.006 Long-term efficacy and safety benefits from treatment with the NMDA antagonist memantine: results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease

✍ H.-J. Moebius; B. Reisberg; F. Schmitt; R. Doody 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 274 KB

P.5.c.001 A 3-year open-label, follow-up

P.5.c.001 A 3-year open-label, follow-up study to evaluate the efficacy and tolerability of sarizotan in Parkinson's disease patients with treatment-associated dyskinesia

✍ T. Müller 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 61 KB